TSG-Based Botanical Drug Platform for Chronic Diseases
TSG-Based Botanical Drug Platform for Chronic Diseases
Project profile curated by GlobalReach Link. Applications are reviewed on a rolling basis.
Project Overview
Innovative botanical drug company advancing first-in-class TCM-derived therapies for chronic heart failure and diabetic macular edema. Lead candidate in Phase III with market exclusivity and strong government backing.
Project Goals
Skills Needed
Competitive Advantage
Globally patented compounds with unique mechanisms not seen in existing therapies
Multi-platform development covering botanical drug extraction synthesi and delivery
Clinical pipeline with first-mover advantage in TCM modernization
Government-supported innovation with established path to NMPA approval and reimbursement
Reasons to Invest & Market Opportunity
• First-in-class 1.1 category botanical drugs targeting large unmet clinical needs
• Phase III trial for heart failure with proven efficacy and safety in Phase II
• Nationally recognized as a Major Industrial Project with strong policy support
• Dual clinical and market exclusivity for lead compounds (10-year protection)
• Product pipeline covers high-growth chronic disease markets with global demand
• Chronic heart failure: 13.7 million patients in China alone; $4B+ projected market by 2030
• DME: 8M+ patients by 2025; current treatment options have poor compliance and limited efficacy
• Global demand for innovative oral and non-invasive chronic disease therapies
Problem & Solution
• Problem:
Existing heart failure and diabetic macular edema (DME) treatments face major limitations in safety, efficacy, and accessibility
• Solution:
Proprietary botanical therapies with novel mechanisms that improve microcirculation, restore energy metabolism, and enhance barrier integrity
Highlights
Lead drug TSG-01 in Phase III trial for chronic heart failure (660 patients)
TSG-02 entering Phase II trial for DME oral delivery format with no competition globally
Published clinical efficacy results statistically significant improvement in heart function (LVEF↑)
Manufacturing and regulatory systems aligned with FDA and NMPA standards
Projected sales exceed $370M by 2031 with 28%+ net profit margin
Exit Strategy
• IPO on STAR Market or Hong Kong Exchange
• Licensing agreements with global pharma partners
• Strategic trade sale or M&A by TCM/pharma players
Apply to Join
Applications are reviewed by the GlobalReach coordination team. Only shortlisted experts will be contacted (NDA for documents).
Sign in may be required before submission.
